The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.
 
Wungki Park
Honoraria - Ipsen
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Jiapeng Chen
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - Bristol-Myers Squibb; Halozyme; Ipsen
 
Danny Khalil
Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40 and in situ vaccination
 
James J. Harding
Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Lilly
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Polaris (Inst)
 
Imane H. El Dika
Consulting or Advisory Role - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Nadeem Riaz
Honoraria - PeerView
Consulting or Advisory Role - Mirati Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Varian Medical Systems
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Bristol-Myers Squibb; Celgene; CytomX Therapeutics (I); Debiopharm Group; Eisai; Exelixis; Flatiron Health; Flatiron Health; Genoscience Pharma; Gilead Sciences; Ipsen; Janssen (I); LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; Pfizer (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; Silenseed (I); Sillajen; SOBI (I); Targovax (I); twoXAR; Vicus Therapeutics; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); Novartis (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
David Paul Kelsen
Consulting or Advisory Role - Kitov Pharmaceuticals; Novo Nordisk; Steba Biotech
Patents, Royalties, Other Intellectual Property - Use of Iron Containing Particles for Imaging by MRI
 
Christine A Iacobuzio-Donahue
Research Funding - Bristol-Myers Squibb (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)